Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study

RCT (n=96) found addition of this orally active antagonist of inhibitor of apoptosis proteins to high-dose cisplatin chemoradiotherapy (CR) was linked to more patients achieving locoregional control 18 months after CR vs. placebo (54% v 33%; OR 2.69; 95% CI 1·13–6·42, p=0·026).


The Lancet Oncology